Our portfolio reflects the structural integrity required to move diagnostics from the lab to the standard of care.
A venture-backed startup with strong molecular POC technology but no structured commercialization path. Unclear CLIA-waived positioning and fragmented strategy risked delayed post-clearance adoption. AdvisoryDx designed evidence framework aligned to payer coverage requirements, built CPT reimbursement and pricing/ROI framework, and created full U.S. go-to-market strategy with placement architecture and channel sequencing.
Early-stage platform with broad panel potential, but no launch sequencing logic. Misaligned regulatory/commercial strategy and unstructured EU/UK entry risked overbuilding the initial product. AdvisoryDx separated initial launch evidence from expanded panel roadmap and developed EU/UK reimbursement logic.
A U.K. diagnostic startup developing a second generation point of care urinalysis platform sought entry into the United States market without a defined commercialization pathway. AdvisoryDx developed detailed U.S. commercialization strategy, designed national distribution model, coordinated CRO engagement, and participated in investor calls supporting Pre Series A fundraising.
Built across the full diagnostic spectrum: molecular and PCR platforms, immunoassay and lateral flow, clinical chemistry and hematology, decentralized and point-of-care testing. Care settings include hospital laboratories, urgent care, physician offices, and reference laboratories.